Zhenping Zhu

Dr. Zhenping Zhu is the current Director at Refuge Biotech. Prior to this, they served as the Director General at the National Engineering Research Center for Antibody Drugs from January 2019 to January 2022. Before that, they were the Executive Vice President, Global Biologics R&D, President & CEO of Kadmon China from August 2010 to January 2017. From February 2009 to July 2010, they were the Vice President and Global Head of Protein Sciences and Design at Novartis. From November 1996 to January 2009, they served as the Vice President, Antibody Technology & Immunology at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. Dr. Zhu has extensive experience in the biotechnology industry and has made significant contributions to the field of antibody drugs.

Zhenping Zhu received their PhD in Immunology and Pathology from Dalhousie University. Zhenping also holds an MSc in Pharmacology from Peking Union Medical College and an MD from Nanchang University.